Evaluation of serum adenosine deaminase and 5′-nucleotidase activities as probable markers in ovarian cancer

Abstract

Adenosine deaminase (ADA) and 5'-nucleotidase (5'-NT) activities were measured in sera of patients with ovarian cancer and patients with benign ovarian tumour. The results were compared with that of a control group consisting of healthy women. ADA levels were significantly increased (P<0.001) in the ovarian cancer group (n=50) but not in the benign group (n=28) when compared to the controls (n=20). The results indicate that ADA and 5'-NT levels may help to differentiate malignant conditions from benign tumours of the ovary in addition to the existing tests such as serum CA-125 levels and histopathological study. KEY WORDS5'-NT, ADA, CA-125, Ovarian cancer.

Untitled

“…Taken together with several lines of investigation from ovarian [6,7] and other cancers [2,3,10] the current study suggests that ADARs (and ADAR in particular) may be useful biomarkers for the diagnosis and management of EOC. Thus, with replication, ADAR genotype status and/ or expression level may serve as a risk factor for EOC.…”

“…Interestingly, gene amplification-associated overexpression of ADAR was recently shown to enhance lung tumorigenesis and contribute to poor outcomes by affecting downstream RNA editing patterns [10]. As mentioned previously, ADAR expression levels have been reported to be significantly higher in serum and/or peritoneal fluid from patients with EOCs compared with benign ovarian tumors [6,7]. Although high-grade serous EOCs from TCGA were not profiled as part of the aforementioned genomic investigations [18,19], Haploreg 4.1 effectively integrates GTEX eQTL results for normal ovary.…”

“…Indeed, altered expression and/or activity of ADAR enzymes has been linked to a variety of conditions, including cardiovascular and neurological diseases and cancers [4]. Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death among women in the United States [5], and ADAR expression levels have been reported to be significantly higher in serum and peritoneal fluid from patients with EOCs compared with benign ovarian tumors [6,7], suggesting ADARs may be useful biomarkers for the diagnosis and management of EOC.…”

Adenosine: An endogenous mediator in the pathogenesis of gynecological cancer

“…In another study, Pragathi et al (2005) measured levels of adenosine deaminase and 5′-nucleotidase in serum of patients suffering from ovarian cancer, benign ovarian tumor and in healthy women. They showed that these two enzymes are up-regulated only in patients suffering from ovarian cancer but not in patients with benign ovarian tumor or in healthy subjects (Pragathi et al, 2005). Consistent with these findings, it has been shown that adenosine deaminase activity is elevated in serum and tumor tissues in skin, breast, and colon cancers (Borzenko, 1991;Koizumi, Iizuka, Aoyagi, & Miura, 1985;Ozturk et al, 1998).…”

“…Moreover, it has been shown that compared to monocytes, the expression of CD39 and CD73 is up‐regulated in tumor associated macrophages which can further suppress the proliferation and cytotoxicity of T cells against cancer cells (Montalbán del Barrio et al, ). Similarly, CD73 is over‐expressed in patients with high‐grade serous ovarian carcinoma, the most common and lethal histological subtype of ovarian cancer, which is associated with poor prognosis and impaired CD8+ T cell‐mediated anti‐tumor immunity in the tumor environment (Pragathi et al, ). To further support the critical role of adenosine in ovarian cancer pathogenesis, Gaudreau, Allard, Turcotte, & Stagg, showed that high levels of CD73 are significantly associated with shorter overall survival in ovarian cancer patients.…”